Publications

1. Tilburt JC, Kim S, Kohli M, Hahbhan M. In Reply. Mayo Clin Proc. 2013 Mar; 88(3):308 Epub 2013 Feb 27. 2310512
   
2. Loprinzi PD, Kohli M. Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc. 2013 Jan; 88(1):11-21. 2289073
   View PubMed
3. Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun; 87(6):540-7. 2250731
   View PubMed
4. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87(3):240-6. 2228965
   View PubMed
5. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019. Epub 2012 Feb 22. 2207285
   View PubMed
6. Nabhan M, Kim S, Shah N, Bagniewski S, Shi Q, Karnes RJ, Weight C, Davis B, Kohli M, Tilburt J. The relationship of the intensity of post-treatment PSA surveillance and prostate cancer outcomes: Results from a population-based cohort. Mayo Clinic Proceedings. 2012 (in press). 2218254
   
7. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An oberservational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. Journal of Men's Health. 2012; 9(3):182-189 Epub 2012 Aug 11. 2265439
   
8. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer. Journal of Men's Health. 2012; 9(3):182-9. 2270421
   
9. Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012; 2012:781459. Epub 2012 Aug 22. 2268808
   View PubMed
10. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13(3):365-77. Epub 2011 May 11. 2163889
    View PubMed
11. Block MS, Kohli M. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol. 2011 Apr; 9(4):335-8. 2163927
    View PubMed
12. Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin expression in prostate: a novel finding. Cancer Invest. 2011 Jan; 29(1):62-7. 2133359
    View PubMed
13. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010 Jan; 85(1):77-86. 1978234
    View PubMed
14. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010; 2(4):e65. Epub 2010 Dec 31. 2133360
    View PubMed
15. Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7(2):101-8. 2136098
    View PubMed
16. Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4. 1950473
    View PubMed
17. Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol. 2008 Jan; 16(1):1-6. 1895456
    View PubMed
18. Kohli M, Viswamitraa S, Schaefer R, Faas FH, Kumar U. Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10):754-5; discussion 756-7. 1895452
    View PubMed
19. Kohli M, Schaefer R. Management of solitary palatal metastasis from renal cell carcinoma. Nat Clin Pract Urol. 2006 Jul; 3(7):392-6; quiz following 396. 1895454
    View PubMed
20. Alikhan MA, Williams R, Udaya K, Shaefer RF, Viswamitra SC, Kohli M. Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun; 13(6):798-800. 1895451
    View PubMed
21. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. 1762781
    View PubMed
22. Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, Suva LJ. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006; 2(6):249-58. 1895455
    View PubMed
23. Kaushal V, Kohli M, Richard D, Chiles W, Mukunyadzi P. Thrombin and thrombin receptor expression in prostate cancer. Prostate. 2005 Oct 21. 1895459
    
24. Alikhan MA, Spencer HJ, Kohli M. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol. 2005 Sep 1; 23(25):6267-8. 1950631
    
25. Challagundla S, Gokden M, Viswamitra S, Kohli M. Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clin Prostate Cancer. 2005 Sep; 4(2):134-7. 1895449
    View PubMed
26. Midathada M, Safar A, Schaefer R, Viswamitra S, Kohli M. Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol. 2005 May; 3(5):425-7. 1895447
    View PubMed
27. Kaushal V, Dennis R, Mukunyadzi P, Siegel E, Johnson D, Kohli M. Stage specific expression of VEGF A and D in prostate cancer. Clin Cancer Res. 2005; 11:1-10. 1895458
    
28. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20. 1665806
    View PubMed
29. Kohli M, Mukunyadzi P, Dennis RA, Johnson DE, Kaushal V. COX-2: an inconsistent therapeutic target in prostate cancer. Uro Oncology. 2004 Sep/Dec; 4(3/4):113-8. 1895457
    
30. Kohli M, Zent C, Hutchins LF, Safar M, Dotson, P, Mehta P. The academic hematology-oncology firm: a model for postgraduate cancer education. J Cancer Educ. 2004 Spr; 19(1):45-9. 1670745
    View PubMed
31. Kohli M, Khan MA, Mehta P, Hutchins L. Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445. 1895444
    View PubMed
32. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost. 2003 Jun; 29(3):301-8. 1892902
    View PubMed
33. Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology. 2003 Apr; 61(4):765-9. 1892904
    View PubMed
34. Kaushal V, Kohli M, Mehta P, Mehta JL. Potential anticancer effects of statins: fact or fiction? Endothelium. 2003; 10(1):49-58. 1895442
    View PubMed
35. Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul 1; 20(13):3042; author reply 3042-3. 1892903
    View PubMed
36. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5. 1341040
    View PubMed
37. Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71. 1341028
    View PubMed